The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer
Highlights
This large-scale integrative study fundamentally advances our understanding of the gut-liver axis by mapping stage-specific microbiome signatures across the entire spectrum of liver disease progression. Key findings include the identification of Veillonella species expansion as a mortality predictor, the discovery of a functional metabolic continuum from hepatitis to hepatocellular carcinoma, and the validation of microbiome-based markers for non-invasive disease staging. The study’s rigorous multicohort design and machine learning approach provide robust evidence for translating microbiome diagnostics into clinical practice.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.